$1.92
-0.055-2.79%
Last update: Oct 22, 6:38 AM
Grace Therapeutics Inc (GRCE) Stock Price, Quote, News & History
GRCENASDAQ
Grace Therapeutics stock drops after FDA flags NDA issues for GTx-104; CMC concerns weigh despite no request for additional clinical data.
You can purchase shares of Grace Therapeutics (NASDAQ:GRCE) through any online brokerage.
Other companies in Grace Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Grace Therapeutics has a consensus price target of $10.00.
The stock price for Grace Therapeutics (NASDAQ: GRCE) is $1.86 last updated October 22, 2026 at 6:38 AM EDT.
There are no upcoming dividends for Grace Therapeutics.
Grace Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Grace Therapeutics.
Grace Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the...
